<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04491864</url>
  </required_header>
  <id_info>
    <org_study_id>018-781</org_study_id>
    <nct_id>NCT04491864</nct_id>
  </id_info>
  <brief_title>DWIBS-MRI: An Adjunct to the Traditional Diagnostic Breast Imaging Evaluation</brief_title>
  <acronym>DWIBS</acronym>
  <official_title>DWIBS-MRI: An Adjunct to the Traditional Diagnostic Breast Imaging Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor Research Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1.1. Primary Objectives&#xD;
&#xD;
        -  To determine if MRI DWIBS can accurately identify suspicious lesions previously&#xD;
           categorized on mammography and sonography as potentially malignant.&#xD;
&#xD;
        -  We will also validate whether DWIBS-MRI ADC values can be used to accurately&#xD;
           differentiate benign from malignant lesions. Additionally, because it is not known&#xD;
           whether tumor type or growth rate (Ki67 values) will affect our results, we will include&#xD;
           these parameters in our analysis.&#xD;
&#xD;
        -  Once we validate the use of DWIBS-MRI ADC values to determine malignancy, can we&#xD;
           establish an ADC threshold value to decrease the number of false positive biopsies that&#xD;
           are performed while still maintaining a zero false negative rate?&#xD;
&#xD;
        -  This study will also assess the correlation between ADC values and the Ki-67&#xD;
           proliferative index of malignant lesions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Anticipated">March 11, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 11, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MRI DWIBS Accuracy</measure>
    <time_frame>1 month</time_frame>
    <description>• To determine if MRI DWIBS can accurately identify suspicious lesions previously categorized on mammography and sonography as potentially malignant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Validate DWIBS-MRI</measure>
    <time_frame>1 month</time_frame>
    <description>• We will also validate whether DWIBS-MRI ADC values can be used to accurately differentiate benign from malignant lesions. Additionally, because it is not known whether tumor type or growth rate (Ki67 values) will affect our results, we will include these parameters in our analysis.</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Genetically female patients age 30 and greater with suspicious BIRADS 4 or BIRADS 5 masses&#xD;
        and/or asymmetries on standard 2D/3D mammogram and ultrasound imaging&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A patient will be eligible for inclusion in this study if she meets all of the&#xD;
             following criteria:&#xD;
&#xD;
               1. &gt;30 years of age&#xD;
&#xD;
               2. Genetic Female&#xD;
&#xD;
               3. Suspected diagnosis of BIRADS 4 or BIRADS 5 masses and/or asymmetries greater&#xD;
                  than 1 centimeter based on standard 2D/3D mammogram and ultrasound imaging.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A patient is ineligible for inclusion in this study if she meets any of the following&#xD;
             criteria:&#xD;
&#xD;
               1. Prior biopsy of suspicious lesion&#xD;
&#xD;
               2. Breast implants&#xD;
&#xD;
               3. Prior history of breast cancer&#xD;
&#xD;
               4. Patient has a pacemaker&#xD;
&#xD;
               5. Contraindications to use of MRI imaging (metal implants, etc.)&#xD;
&#xD;
               6. Woman pregnant or lactating&#xD;
&#xD;
               7. Calcifications as only findings present for a suspicious lesion&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>The study population under investigation are for participants who are genetically female.</gender_description>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mariana Hurutado, RN</last_name>
    <phone>214.820.7755</phone>
    <email>Mariana.Hurutado@BSWHealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Insitute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Hurutado</last_name>
      <phone>214-820-7755</phone>
      <email>Mariana.Hurutado@BSWHealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2020</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor Research Institute</investigator_affiliation>
    <investigator_full_name>Sean Raj</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

